<DOC>
	<DOCNO>NCT00038532</DOCNO>
	<brief_summary>The purpose study study amprenavir/ritonavir , saquinavir/ritonavir efavirenz HIV-infected patient follow failure Kaletra ( ABT-378/ritonavir ) first protease inhibitor base HAART .</brief_summary>
	<brief_title>Amprenavir/Ritonavir , Saquinavir/Ritonavir Efavirenz HIV-Infected Subjects Following Failure With Kaletra ( ABT-378/Ritonavir ) Their First Protease Inhibitor Based HAART</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Inclusion : Remain present antiHIV drug screen new regimen start . Have viral load least 1,000 copies/ml 2 recent test least 24 week lopinavir/ritonavir still . Have HIV show reduce susceptibility lopinavir . Are least 18 year old . Are presently ill. Have treat opportunistic infection within 30 day screen . Agree take certain drug agree inform get permission doctor take medicine , counter medicine , herbal medicine , alcohol recreational drug . Agree use accept barrier method birth control . Exclusion : Female subject pregnant lactating . Have take protease inhibitor lopinavir/ritonavir two week . Are take chemotherapy . Have medical problem pancreas . Have screen study within past 12 week . Appear unsuitable opinion doctor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>treatment experience</keyword>
	<keyword>HIV</keyword>
</DOC>